Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Cancer Metastasis Rev. 2012 Dec;31(3-4):493-500. doi: 10.1007/s10555-012-9360-1.
Scaffolding proteins such as SSeCKS/Gravin/AKAP12 ("AKAP12") are thought to control oncogenic signaling pathways by regulating key mediators in a spatiotemporal manner. The downregulation of AKAP12 in many human cancers, often associated with promoter hypermethylation, or the loss of its locus at 6q24-25.2, correlates with progression to malignancy and metastasis. The forced re-expression of AKAP12 in cancer cell lines suppresses in vitro parameters of oncogenic growth, invasiveness, and cell motility through its ability to scaffold protein kinase C (PKC), F-actin, cyclins, Src, and phosphoinositides, and possibly through additional scaffolding domains for PKA, calmodulin, β1,4-galactosyltransferase-polypeptide-1, β2-adrenergic receptors, and cAMP-specific 3',5'-cyclic phosphodiesterase 4D. Moreover, AKAP12 re-expression in tumor models results in metastasis suppression through the inhibition of Src-regulated, VEGF-mediated neovascularization at distal sites. The current review will describe the emerging understanding of how AKAP12 regulates cellular senescence and oncogenic progression at the level of tumor cells and tumor-associated microenvironment via its multiple scaffolding functions.
支架蛋白,如 SSeCKS/Gravin/AKAP12("AKAP12"),被认为通过时空调节关键介质来控制致癌信号通路。AKAP12 在许多人类癌症中的下调,通常与启动子超甲基化或其在 6q24-25.2 位点的缺失有关,与恶性肿瘤的进展和转移相关。在癌细胞系中强制重新表达 AKAP12 通过其支架蛋白激酶 C(PKC)、F-肌动蛋白、细胞周期蛋白、Src 和磷酸肌醇的能力,抑制体外致癌生长、侵袭和细胞迁移的参数,并且可能通过 PKA、钙调蛋白、β1,4-半乳糖基转移酶多肽-1、β2-肾上腺素能受体和 cAMP 特异性 3',5'-环磷酸二酯酶 4D 的其他支架结构域。此外,在肿瘤模型中重新表达 AKAP12 可通过抑制 Src 调节的、VEGF 介导的远端部位新血管生成来抑制转移。本综述将描述如何通过其多种支架功能,在肿瘤细胞和肿瘤相关微环境水平上,AKAP12 调节细胞衰老和致癌进展的新认识。